Maze Therapeutics (NASDAQ:MAZE) CMO Sells $16,480.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 412 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $40.00, for a total value of $16,480.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Trading Down 3.5%

Shares of Maze Therapeutics stock opened at $38.95 on Friday. The company has a fifty day simple moving average of $37.58 and a 200-day simple moving average of $25.65. The stock has a market cap of $1.87 billion and a price-to-earnings ratio of -1.86. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently bought and sold shares of MAZE. Woodline Partners LP purchased a new position in Maze Therapeutics during the 1st quarter worth $10,229,000. Vanguard Group Inc. raised its holdings in Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares in the last quarter. Marshall Wace LLP lifted its position in Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period. ArrowMark Colorado Holdings LLC acquired a new stake in Maze Therapeutics in the third quarter valued at about $14,135,000. Finally, Octagon Capital Advisors LP purchased a new stake in Maze Therapeutics in the 1st quarter valued at approximately $5,153,000.

Analyst Upgrades and Downgrades

Several research firms have commented on MAZE. Guggenheim reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Friday, December 19th. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. BTIG Research increased their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Wedbush raised their price objective on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $43.38.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.